1.Risk-adapted scoring model to identify candidates benefiting from adjuvant chemotherapy after radical nephroureterectomy for localized upper urinary tract urothelial carcinoma: A multicenter study
Sung Jun SOU ; Ja Yoon KU ; Kyung Hwan KIM ; Won Ik SEO ; Hong Koo HA ; Hui Mo GU ; Eu Chang HWANG ; Young Joo PARK ; Chan Ho LEE
Investigative and Clinical Urology 2025;66(2):114-123
Purpose:
Adjuvant chemotherapy (AC) is recommended for muscle-invasive or lymph node-positive upper urinary tract urothelial carcinoma (UTUC) after radical nephroureterectomy (RNU). However, disease recurrences are frequently observed in pT1 disease, and AC may increase the risk of overtreatment in pT2 UTUC patients. This study aimed to validate a risk-adapted scoring model for selecting UTUC patients with ≤pT2 disease who would benefit from AC.
Materials and Methods:
We retrospectively analyzed 443 ≤pT2 UTUC patients who underwent RNU. A risk-adapted scoring model was applied, categorizing patients into low- or high-risk groups. Recurrence-free survival (RFS) and cancer-specific survival (CSS) were analyzed according to risk group.
Results:
Overall, 355 patients (80.1%) and 88 patients (19.9%) were categorized into the low- and high-risk groups, respectively, with the latter having higher pathological stages, concurrent carcinoma in situ, and synchronous bladder tumors. Disease recurrence occurred in 45 patients (10.2%), among whom 19 (5.4%) and 26 (29.5%) belonged to the low- and high-risk groups, respectively (p<0.001). High-risk patients had significantly shorter RFS (64.3% vs. 93.6% at 60 months; hazard ratio [HR] 13.66; p<0.001) and worse CSS (80.7% vs. 91.5% at 60 months; HR 4.25; p=0.002). Multivariate analysis confirmed that pT2 stage and the high-risk group were independent predictors of recurrence and cancer-specific death (p<0.001). Decision curve analysis for RFS showed larger net benefits with our model than with the T stage model.
Conclusions
The risk-adapted scoring model effectively predicts recurrence and identifies optimal candidates for AC post RNU in non-metastatic UTUC.
2.Analgesic effect of structured anal skin care for perianal dermatitis after low anterior resection in the rectal cancer patients: prospective, single-center, open-label, therapeutic confirmatory, randomized clinical trial
Gyung Mo SON ; In Young LEE ; Mi Sook YUN ; Jung-Hea YOUN ; Hong Min AN ; Kyung Hee KIM ; Seung Mi YEO ; Bokyung KU ; Myeong Suk KWON ; Kun Hyung KIM
Annals of Surgical Treatment and Research 2022;103(6):360-371
Purpose:
This prospective, single-center, open-label, therapeutic confirmatory, randomized clinical trial aimed to assess the alleviation of anal pain by applying structured anal skin care including skin protectants in rectal cancer patients with low anterior resection syndrome (LARS) combined with anal pain.
Methods:
From December 2017 to May 2020, 42 patients with LARS (scores of ≥21) and anal pain (visual analogue scale [VAS] score of ≥3) were randomly assigned and observed for 4 weeks. The conventional treatment consisted of dietary management, sitz baths, prohibition of anal scrubbing, loperamide, and dioctahedral smectite. In the anal care group, cleanser, barrier cream, and barrier spray were applied to the anal skin after defecation following the conventional treatment. The primary outcome was analgesic effect on anal pain after 2 weeks of structured treatment (anal care group) or conventional (control group). The cutoff for analgesic effect was a decrease in the anal pain score (VAS score of ≥2 or ≥30% reduction).
Results:
As a primary outcome, the analgesic effect was significantly higher in the anal care group (P = 0.034). The incontinence-associated dermatitis skin condition score was significantly improved in the anal care group than control group after 4 weeks (P = 0.023). There were no significant differences in LARS scores and quality of life scores between 2 groups.
Conclusion
Structured anal skin care has a significant analgesic effect in reducing anal pain and improving anal skin conditions in patients with LARS after rectal cancer surgery.
3.Diagnosis and Treatment of Growth Hormone Deficiency: A Position Statement from Korean Endocrine Society and Korean Society of Pediatric Endocrinology
Jung Hee KIM ; Hyun Wook CHAE ; Sang Ouk CHIN ; Cheol Ryong KU ; Kyeong Hye PARK ; Dong Jun LIM ; Kwang Joon KIM ; Jung Soo LIM ; Gyuri KIM ; Yun Mi CHOI ; Seong Hee AHN ; Min Ji JEON ; Yul HWANGBO ; Ju Hee LEE ; Bu Kyung KIM ; Yong Jun CHOI ; Kyung Ae LEE ; Seong-Su MOON ; Hwa Young AHN ; Hoon Sung CHOI ; Sang Mo HONG ; Dong Yeob SHIN ; Ji A SEO ; Se Hwa KIM ; Seungjoon OH ; Sung Hoon YU ; Byung Joon KIM ; Choong Ho SHIN ; Sung-Woon KIM ; Chong Hwa KIM ; Eun Jig LEE
Endocrinology and Metabolism 2020;35(2):272-287
Growth hormone (GH) deficiency is caused by congenital or acquired causes and occurs in childhood or adulthood. GH replacement therapy brings benefits to body composition, exercise capacity, skeletal health, cardiovascular outcomes, and quality of life. Before initiating GH replacement, GH deficiency should be confirmed through proper stimulation tests, and in cases with proven genetic causes or structural lesions, repeated GH stimulation testing is not necessary. The dosing regimen of GH replacement therapy should be individualized, with the goal of minimizing side effects and maximizing clinical improvements. The Korean Endocrine Society and the Korean Society of Pediatric Endocrinology have developed a position statement on the diagnosis and treatment of GH deficiency. This position statement is based on a systematic review of evidence and expert opinions.
4.Sulfuretin Prevents Obesity and Metabolic Diseases in Diet Induced Obese Mice.
Suji KIM ; No Joon SONG ; Seo Hyuk CHANG ; Gahee BAHN ; Yuri CHOI ; Dong Kwon RHEE ; Ui Jeong YUN ; Jinhee CHOI ; Jeon LEE ; Jae Hyuk YOO ; Donghan SHIN ; Ki Moon PARK ; Hee KANG ; Sukchan LEE ; Jin Mo KU ; Yoon Shin CHO ; Kye Won PARK
Biomolecules & Therapeutics 2019;27(1):107-116
The global obesity epidemic and associated metabolic diseases require alternative biological targets for new therapeutic strategies. In this study, we show that a phytochemical sulfuretin suppressed adipocyte differentiation of preadipocytes and administration of sulfuretin to high fat diet-fed obese mice prevented obesity and increased insulin sensitivity. These effects were associated with a suppressed expression of inflammatory markers, induced expression of adiponectin, and increased levels of phosphorylated ERK and AKT. To elucidate the molecular mechanism of sulfuretin in adipocytes, we performed microarray analysis and identified activating transcription factor 3 (Atf3) as a sulfuretin-responsive gene. Sulfuretin elevated Atf3 mRNA and protein levels in white adipose tissue and adipocytes. Consistently, deficiency of Atf3 promoted lipid accumulation and the expression of adipocyte markers. Sulfuretin’s but not resveratrol’s anti-adipogenic effects were diminished in Atf3 deficient cells, indicating that Atf3 is an essential factor in the effects of sulfuretin. These results highlight the usefulness of sulfuretin as a new anti-obesity intervention for the prevention of obesity and its associated metabolic diseases.
Activating Transcription Factor 3
;
Adipocytes
;
Adiponectin
;
Adipose Tissue, White
;
Animals
;
Diet*
;
Insulin Resistance
;
Metabolic Diseases*
;
Mice
;
Mice, Obese*
;
Microarray Analysis
;
Obesity*
;
RNA, Messenger
5.Treatment by Transradial Urokinase Infusion and Percutaneus Transhepatic Thrombectomy in Superior Mesenteric Veno us Thrombosis with Intestinal Infarction
Suk Hyang BAE ; Kyung Han KIM ; Jin Yeon WHANG ; Jeong Min LEE ; Jeong Min KIM ; Jeong Mo KU ; Jonghun LEE
Korean Journal of Medicine 2018;93(1):55-60
Mesenteric venous thrombosis has a low prevalence and nonspecific clinical symptoms, and it may cause bowel infarction and death. Early diagnosis and prompt surgical intervention with anticoagulants are important to patients. We examined a 27-year-old woman complaining of diffuse abdominal pain and hematochezia, and diagnosed extensive mesenteric venous thrombosis with intestinal infarction and pulmonary thromboembolism. In light of the patient's symptoms, an operation seemed necessary. However, because of the high risk of mortality, we decided to look for another option. The patient was successfully treated with intensive medical care and a radiological procedure in spite of intestinal infarction.
Abdominal Pain
;
Adult
;
Anticoagulants
;
Early Diagnosis
;
Female
;
Gastrointestinal Hemorrhage
;
Humans
;
Infarction
;
Mesenteric Ischemia
;
Mesenteric Vascular Occlusion
;
Mortality
;
Prevalence
;
Pulmonary Embolism
;
Thrombectomy
;
Thrombolytic Therapy
;
Thrombosis
;
Urokinase-Type Plasminogen Activator
6.Synergistic effect of ribavirin and vaccine for protection during early infection stage of foot-and-mouth disease
Joo Hyung CHOI ; Kwiwan JEONG ; Su Mi KIM ; Mi Kyeong KO ; Su Hwa YOU ; Young S LYOO ; Byounghan KIM ; Jin Mo KU ; Jong Hyeon PARK
Journal of Veterinary Science 2018;19(6):788-797
In many countries, vaccines are used for the prevention of foot-and-mouth disease (FMD). However, because there is no protection against FMD immediately after vaccination, research and development on antiviral agents is being conducted to induce protection until immunological competence is produced. This study tested whether well-known chemicals used as RNA virus treatment agents had inhibitory effects on FMD viruses (FMDVs) and demonstrated that ribavirin showed antiviral effects against FMDV in vitro/in vivo. In addition, it was observed that combining the administration of the antiviral agents orally and complementary therapy with vaccines synergistically enhanced antiviral activity and preserved the survival rate and body weight in the experimental animals. Antiviral agents mixed with an adjuvant were inoculated intramuscularly along with the vaccines, thereby inhibiting virus replication after injection and verifying that it was possible to induce early protection against viral infection prior to immunity being achieved through the vaccine. Finally, pigs treated with antiviral agents and vaccines showed no clinical signs and had low virus excretion. Based on these results, it is expected that this combined approach could be a therapeutic and preventive treatment for early protection against FMD.
Animals
;
Antiviral Agents
;
Body Weight
;
Foot-and-Mouth Disease
;
Immunocompetence
;
Ribavirin
;
RNA Viruses
;
Survival Rate
;
Swine
;
Vaccination
;
Vaccines
;
Virus Replication
7.Treatment by Transradial Urokinase Infusion and Percutaneus Transhepatic Thrombectomy in Superior Mesenteric Veno us Thrombosis with Intestinal Infarction
Suk Hyang BAE ; Kyung Han KIM ; Jin Yeon WHANG ; Jeong Min LEE ; Jeong Min KIM ; Jeong Mo KU ; Jonghun LEE
Korean Journal of Medicine 2018;93(1):55-60
Mesenteric venous thrombosis has a low prevalence and nonspecific clinical symptoms, and it may cause bowel infarction and death. Early diagnosis and prompt surgical intervention with anticoagulants are important to patients. We examined a 27-year-old woman complaining of diffuse abdominal pain and hematochezia, and diagnosed extensive mesenteric venous thrombosis with intestinal infarction and pulmonary thromboembolism. In light of the patient's symptoms, an operation seemed necessary. However, because of the high risk of mortality, we decided to look for another option. The patient was successfully treated with intensive medical care and a radiological procedure in spite of intestinal infarction.
8.Saeng-Kankunbi-Tang () protects liver against oxidative damage through activation of ERK/Nrf2 pathway.
In Woo LEE ; Hee Yoon CHOI ; Ju-Hee LEE ; Sun-Dong PARK ; Seung Mo KIM ; Sae Kwang KU ; Rong-Jie ZHAO ; Sang Chan KIM ; Young Woo KIM ; Hong Sik CHOI
Chinese journal of integrative medicine 2016;22(8):619-628
OBJECTIVETo investigate the cytoprotective effects of Saeng-kankunbi-tang (, SKT), a herbal prescription consisting of Artemisia capillaris and Alisma canaliculatum, and its underlying mechanism involved.
METHODSIn mice, blood biochemistry and histopathology were assessed in carbon tetrachloride (CCl4)-induced oxidative hepatic injury in vivo. The animal groups included vehicle-treated control, CCl4, SKT 500 mg/(kg day) CCl4+SKT 200 or 500 mg/(kg day). In HepG2 cell, tert-butyl hydroperoxide (tBHP) induced severe oxidative stress and mitochondrial dysfunction in vitro. The cyto-protective effects of SKT were determined by 3-(4,5-dimethylthiazol)-2,5-diphenyltetrazolium bromide (MTT) assay, flfluorescence activated cell sorting analysis and western blotting.
RESULTSThe administration of SKT prevented liver damage induced by CCl4 in mice, by inhibition of hepatocyte degeneration and inflflammatory cell infifiltration as well as plasma parameters such as alanine aminotransferase (P<0.01). Moreover, treatment with tBHP induced hepatocyte death and cellular reactive oxygen species production in hepatocyte cell line. However, SKT pretreatment (30-300 μg/mL) reduced this cell death and oxidative stress (P<0.01). More importantly, SKT inhibited the ability of tBHP to induce changes in mitochondrial membrane transition in cell stained with rhodamine 123 P<0.01). Furthermore, treatment with SKT induced extracellular signal-regulated kinases-mediated nuclear factor erythroid-2-related factor 2 (Nrf2) activation as well as the expressions of heme oxygenase 1 and glutamate- cystein ligase catalytic, Nrf2 target genes.
CONCLUSIONSSKT has the ability to protect hepatocyte against oxidative stress and mitochondrial damage mediated by Nrf2 activation.
Animals ; Antioxidants ; pharmacology ; Carbon Tetrachloride ; Cell Death ; drug effects ; Drugs, Chinese Herbal ; pharmacology ; Extracellular Signal-Regulated MAP Kinases ; metabolism ; Hep G2 Cells ; Humans ; Liver ; drug effects ; enzymology ; pathology ; MAP Kinase Signaling System ; drug effects ; Mice, Inbred C57BL ; Mitochondria ; drug effects ; metabolism ; NF-E2-Related Factor 2 ; metabolism ; Oxidative Stress ; drug effects ; Peroxides ; Phosphorylation ; drug effects ; Protective Agents ; pharmacology ; Reactive Oxygen Species ; metabolism
9.Ethical Issues Recognized by Critical Care Nurses in the Intensive Care Units of a Tertiary Hospital during Two Separate Periods.
Dong Won PARK ; Jae Young MOON ; Eun Yong KU ; Sun Jong KIM ; Young Mo KOO ; Ock Joo KIM ; Soon Haeng LEE ; Min Woo JO ; Chae Man LIM ; John David ARMSTRONG ; Younsuck KOH
Journal of Korean Medical Science 2015;30(4):495-501
This research aimed to investigate the changes in ethical issues in everyday clinical practice recognized by critical care nurses during two observation periods. We conducted a retrospective analysis of data obtained by prospective questionnaire surveys of nurses in the intensive care units (ICU) of a tertiary university-affiliated hospital in Seoul, Korea. Data were collected prospectively during two different periods, February 2002-January 2003 (Period 1) and August 2011-July 2012 (Period 2). Significantly fewer cases with ethical issues were reported in Period 2 than in Period 1 (89 cases [2.1%] of 4,291 ICU admissions vs. 51 [0.5%] of 9,302 ICU admissions, respectively; P < 0.001). The highest incidence of cases with identified ethical issues in both Periods occurred in MICU. The major source of ethical issues in Periods 1 and 2 was behavior-related. Among behavior-related issues, inappropriate healthcare professional behavior was predominant in both periods and mainly involved resident physicians. Ethical issue numbers regarding end-of-life (EOL) care significantly decreased in the proportion with respect to ethical issues during Period 2 (P = 0.044). In conclusion, the decreased incidence of cases with identified ethical issues in Period 2 might be associated with ethical enhancement related with EOL and improvements in the ICU care environment of the studied hospital. However, behavior-related issues involving resident physicians represent a considerable proportion of ethical issues encountered by critical care nurses. A systemic approach to solve behavior-related issues of resident physicians seems to be required to enhance an ethical environment in the studied ICU.
Critical Care Nursing/*ethics
;
Humans
;
*Intensive Care Units
;
Nurses
;
Retrospective Studies
;
Terminal Care
;
Tertiary Care Centers
10.alpha-Asarone Ameliorates Memory Deficit in Lipopolysaccharide-Treated Mice via Suppression of Pro-Inflammatory Cytokines and Microglial Activation.
Jung Won SHIN ; Young Jin CHEONG ; Yong Mo KOO ; Sooyong KIM ; Chung Ku NOH ; Young Ha SON ; Chulhun KANG ; Nak Won SOHN
Biomolecules & Therapeutics 2014;22(1):17-26
alpha-Asarone exhibits a number of pharmacological actions including neuroprotective, anti-oxidative, anticonvulsive, and cognitive enhancing action. The present study investigated the effects of alpha-asarone on pro-inflammatory cytokines mRNA, microglial activation, and neuronal damage in the hippocampus and on learning and memory deficits in systemic lipopolysaccharide (LPS)-treated C57BL/6 mice. Varying doses of alpha-asarone was orally administered (7.5, 15, or 30 mg/kg) once a day for 3 days before the LPS (3 mg/kg) injection. alpha-Asarone significantly reduced TNF-alpha and IL-1beta mRNA at 4 and 24 hours after the LPS injection at dose of 30 mg/kg. At 24 hours after the LPS injection, the loss of CA1 neurons, the increase of TUNEL-labeled cells, and the up-regulation of BACE1 expression in the hippocampus were attenuated by 30 mg/kg of alpha-asarone treatment. alpha-Asarone significantly reduced Iba1 protein expression in the hippocampal tissue at a dose of 30 mg/kg. alpha-Asarone did not reduce the number of Iba1-expressing microglia on immunohistochemistry but the average cell size and percentage areas of Iba1-expressing microglia in the hippocampus were significantly decreased by 30 mg/kg of alpha-asarone treatment. In the Morris water maze test, alpha-asarone significantly prolonged the swimming time spent in the target and peri-target zones. alpha-Asarone also significantly increased the number of target heading and memory score in the Morris water maze. The results suggest that inhibition of pro-inflammatory cytokines and microglial activation in the hippocampus by alpha-asarone may be one of the mechanisms for the alpha-asarone-mediated ameliorating effect on memory deficits.
Animals
;
Cell Size
;
Cytokines*
;
Head
;
Hippocampus
;
Immunohistochemistry
;
Learning
;
Maze Learning
;
Memory
;
Memory Disorders*
;
Mice*
;
Microglia
;
Neurons
;
RNA, Messenger
;
Swimming
;
Tumor Necrosis Factor-alpha
;
Up-Regulation

Result Analysis
Print
Save
E-mail